A first-of-its-kind study found that customers overpaid an average $7.69 on nearly a quarter of prescriptions by using their insurance instead of cash.
A Kaiser Health News analysis shows that hundreds of people have glided through the revolving door that connects the drug industry to Capitol Hill and to the Department of Health and Human Services.
DebugScreen: mobile
{
"author": {
"name": "Sydney Lupkin Kaiser Health News",
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"description": "",
"imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
"estimate": 7,
"social": [],
"articles": [
{
"uri": "/2019/08/07/how-generic-is-that-generic-drug-really/",
"title": "How 'generic' is that generic drug, really?",
"byline": "Jay Hancock, Kaiser Health News and Sydney Lupkin, Kaiser Health News",
"kicker": "Market Insights",
"prettyDate": "August 07, 2019",
"timeToRead": "8 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2019/04/Pills-Bottle-Article-201904161602.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/jay-hancock-kaiser-health-news/",
"name": "Jay Hancock, Kaiser Health News"
},
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [
{
"uri": "/market-insights/",
"sectionName": "Market Insights"
}
],
"summary": "Of all the ways drug companies try to protect sales as patents expire, authorized generics are by far the most profitable, ",
"body": null
},
{
"uri": "/2019/04/09/is-killing-drug-rebates-really-the-answer/",
"title": "Is killing drug rebates really the answer to high drug prices?",
"byline": "Sydney Lupkin, Kaiser Health News",
"kicker": "Market Insights",
"prettyDate": "April 09, 2019",
"timeToRead": "6 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/12/pill-money-investing-investments-health-pharma.jpg",
"width": "616",
"height": "411"
},
"authors": [
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [
{
"uri": "/market-insights/",
"sectionName": "Market Insights"
}
],
"summary": "CVS Health says it's tried offering drug plans without rebates, but consumers don't want them. ",
"body": null
},
{
"uri": "/2019/01/23/secret-rebate-traps-keep-consumers-from-saving-on-generic-medications/",
"title": "Secret 'rebate traps' keep consumers from saving on generic medications",
"byline": "Jay Hancock, Kaiser Health News and Sydney Lupkin, Kaiser Health News",
"kicker": "Market Insights",
"prettyDate": "January 23, 2019",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/06/prescription-pill-dollars-getty-e1530304375110.jpg",
"width": "620",
"height": "413"
},
"authors": [
{
"webUrl": "/author/profile/jay-hancock-kaiser-health-news/",
"name": "Jay Hancock, Kaiser Health News"
},
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [
{
"uri": "/market-insights/",
"sectionName": "Market Insights"
}
],
"summary": "New research is turning up evidence of rebates distorting the market, often leaving effective, less expensive generics off of formularies.",
"body": null
},
{
"uri": "/2018/05/30/pfizer-settles-copay-assistance-kickback-case-for/",
"title": "Pfizer settles copay-assistance kickback case for $24M",
"byline": "Sydney Lupkin, Kaiser Health News",
"kicker": "News",
"prettyDate": "May 30, 2018",
"timeToRead": "4 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/05/Pfizer.jpg",
"width": "616",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [
{
"uri": "/news/",
"sectionName": "News"
}
],
"summary": "The company is not admitting wrongdoing or liability as part of its agreement with the Department of Justice.",
"body": null
},
{
"uri": "/2018/05/24/drugmaker-shenanigans-blamed-for-lag-in-generic-dr/",
"title": "Drugmaker 'shenanigans' blamed for lag in generic drug development",
"byline": "Sydney Lupkin, Kaiser Health News",
"kicker": "Investigation",
"prettyDate": "May 24, 2018",
"timeToRead": "6 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/04/DrugVials.jpg",
"width": "600",
"height": "400"
},
"authors": [
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [
{
"uri": "/investigation/",
"sectionName": "Investigation"
}
],
"summary": "By delaying development of generics, drugmakers can maintain their monopolies and keep prices high.",
"body": null
},
{
"uri": "/2018/03/14/patients-overpay-for-prescriptions-23-of-the-time/",
"title": "Patients overpay for prescriptions 23 percent of the time",
"byline": "Sydney Lupkin, Kaiser Health News",
"kicker": "Analysis",
"prettyDate": "March 14, 2018",
"timeToRead": "5 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/02/DrugPrices.jpg",
"width": "600",
"height": "400"
},
"authors": [
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [
{
"uri": "/analysis/",
"sectionName": "Analysis"
}
],
"summary": "A first-of-its-kind study found that customers overpaid an average $7.69 on nearly a quarter of prescriptions by using their insurance instead of cash.",
"body": null
},
{
"uri": "/2018/01/25/the-cozy-relationship-between-capitol-hill-and-big/",
"title": "The cozy relationship between Capitol Hill and Big Pharma",
"byline": " Sydney Lupkin, Kaiser Health News ",
"kicker": "",
"prettyDate": "January 25, 2018",
"timeToRead": "6 minute",
"image": {
"uri": "",
"width": "",
"height": ""
},
"authors": [
{
"webUrl": "/author/profile/sydney-lupkin-kaiser-health-news/",
"name": "Sydney Lupkin, Kaiser Health News"
}
],
"kickerNode": [],
"summary": "A Kaiser Health News analysis shows that hundreds of people have glided through the revolving door that connects the drug industry to Capitol Hill and to the Department of Health and Human Services.",
"body": null
}
]
}
}
